Metformina Accord

Metformin Hydrochloride, the active ingredient in Metformina Accord, is a Biguanide presented as a tablet (strength unspecified) for oral use. It reduces hepatic glucose production and improves insulin sensitivity to treat type 2 diabetes mellitus in adults.

GNH USA supplies Metformina Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina Accord is used in the management of disorders related to insulin resistance and hyperglycaemia. - Type 2 diabetes mellitus: lowers fasting plasma glucose and HbA1c to improve overall glycaemic control. - Prediabetes: helps delay progression to overt diabetes by enhancing insulin sensitivity. - Polycystic ovary syndrome (off‑label): may improve menstrual regularity and metabolic parameters.

Metformina Accord may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and diarrhoea. - Metallic taste in the mouth. - Decreased appetite. - Mild headache. - Weight loss.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe hypoglycaemia when combined with insulin or secretagogues. - Hepatic dysfunction. - Skin rash or hypersensitivity reactions. - Vitamin B12 deficiency with long‑term use.

Before initiating Metformina Accord, consider the following safety measures. - Renal function: assess creatinine clearance; avoid in severe renal impairment. - Hepatic disease: use with caution as liver dysfunction may increase risk of lactic acidosis. - Cardiovascular status: monitor in patients with unstable heart failure. - Pregnancy and lactation: evaluate risk‑benefit; generally avoided unless clearly needed. - Drug interactions: review concomitant medications for potential additive effects. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Metformina Accord can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Certain antiretrovirals (e.g., didanosine): heightened risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and potassium levels. - Alcohol: potentiates lactic acidosis risk. - Thyroid hormones: may require dose adjustments.